Key Takeaways
- A quarter of operational setbacks: Revenue fell to INR425 crores (vs INR471 crores YoY) as Atali plant stabilization delays and API softness hit both the top and bottom line, with PAT nearly halving to INR44 crores.
- Atali is the central drag, with a Q4 fix promised: Validation challenges from new staff and larger batch sizes at the new plant added opex and full depreciation, compressing margins; management expects resolution by the end of Q4.
- Xanthine tailwinds are building but not yet banked: China's rebate withdrawal could lift prices 8-10%, and a 20% U.S. duty on Chinese product gives a structural edge, but the benefit is still in the future.
- CDMO confidence holds despite a large deferred shipment: A INR49-crore shipment slipped on DAP incoterm timing, a one-off that masks underlying momentum; management remains confident on FY26 CDMO guidance though exceeding it now looks difficult.
- What to watch next quarter: Whether Atali actually stabilizes by the Q4 deadline, the pace of API recovery toward the INR200-crore quarterly milestone, and any concrete Xanthine price movement following China's policy shift.
Atali Plant: The Quarter's Central Problem
- Startup hiccups, not structural failure: Validation of several products faced challenges because the plant runs newer staff, all-new reactions, and much larger batch sizes than legacy sites. Corrective actions are already in place.
- The cost bleed is material: Full depreciation on INR300 crores of capitalization has kicked in, plus a monthly opex of roughly INR1.5 crores for the validation program, all without corresponding revenue.
- Resolution timeline is near-term: Management expects the startup issues to be resolved by the end of Q4 FY26, which would unlock intermediate capacity and relieve the opex drag.
- FY27 role expands: More products will be validated from Atali in FY27, helping intermediate capacity increase; at least one new CDMO block is also planned at the site with capex approval expected soon.
Gogri: "We have good visibility. Of course, we have to keep our finger crossed. We - our partners have to make sure that their launch drugs are being successful and they don't have any hiccups. So everything is contingent to how they are performing, post launch."
API Business: Volume Over Price
- The structural reality: Generic API prices never increase, they only decline, so the strategy is to grow capacity and launch new products. Block 5 expansion is complete, a steroid line is being debottlenecked, and oncology block debottlenecking is planned.
- This quarter's softness unpacked: On a like-for-like standalone basis, API and intermediate revenue dropped roughly 5-6%, partly because last year's launch partners took significant quantities and are now slower to reorder. Intermediate capacity was also constrained while the combined facility ran CDMO operations.
- Recovery path is gradual: Management sees early indications of recovery but expects it will take a couple more quarters to reach the INR200-crore quarterly run rate, the first milestone on the way back.
- FY27 looks better on paper: Launches like Apixaban and other anticancer products are slated for 2026, with some APIs seeing patent expiry around 2027-28, setting up a stronger year.
Gogri: "See, generic API business, the prices never increase. They always go down only. Ultimately, the game has to be played where you increase the capacity."
Xanthine: A Structural Tailwind in Early Innings
- China policy shift is the catalyst: China announced withdrawal of a 13% rebate benefit on caffeine and its salts, which management expects will push prices up by at least 8-10%. Spot markets have already seen a roughly 5% increase from lower levels, and pricing is believed to have bottomed out.
- A U.S. duty advantage adds edge: Indian caffeine enters the U.S. duty-free while Chinese product faces a 20% duty, creating a competitive moat in a key market.
- Capacity is ramping ahead of demand: The current operating run rate reached 6,000 tonnes per month this quarter, up from 5,000 via debottlenecking. Mechanical completion of the expansion to 9,000 tonnes per annum is targeted for end-March 2026, with incremental capacity available in Q1 FY27 and utilization rising progressively.
- The ambition is top-three global scale: Management wants to reach 85-90% of the 9,000-tonne capacity by FY28, while always keeping some free capacity. Overall utilization will average 50-60% for the year.
Gogri: "China has announced that they will withdraw the benefit - rebate benefit on caffeine and its salts. With that rebate withdrawal, overall 13% benefit that is getting accrued to the Chinese manufacturers when they export the API that will go away. And we are hoping that this will push the prices of the product up by at least 8% to 10% in future."
CDMO: Deferred, Not Derailed
- A large one-off deferral distorts the quarter: A INR49-crore shipment (INR30 crores COGS) was deferred because DAP incoterm books revenue at delivery, not shipment. Most shipments use air freight or CIF/FOB terms where revenue is recognized at shipment, so this is not a recurring issue.
- FY26 guidance is intact but stretched: Management remains confident of meeting CDMO revenue guidance for FY26, though exceeding it now looks difficult because certain project deliveries have been pushed by a few months.
- The pipeline is concentrated but deepening: 80% of CDMO sales come from 7-8 projects, with wallet share reaching 60-70% on a few innovator partnerships. The project list of 60 is dynamic: non-progressing projects are pruned while newer ones enter the commercial range.
- FY27 growth expected in the 30-40% band: Management targets INR1,000 crores in CDMO sales and sees FY27 growth similar to FY26, with customer count expected to rise in calendar year 2026. A new CDMO block at Atali will support this.
Margins & Earnings: A Q4 Rebound Is Priced In
- The 9-month trend is steadier than Q3 suggests: Gross margins and EBITDA margins are trending at nearly the same level over nine months, implying the quarter's compression is partly timing.
- Other expenses will normalize: The significant rise in other expenses is driven by the Atali site and a new leased site where conducting fees are being paid. Once Atali stabilizes and ramps, this line should return to 21-22% of sales.
- FY26 EBITDA now seen as flat to marginally up: The revision from earlier growth expectations reflects API degrowth, CDMO pushbacks, and Xanthine performing as targeted. This implies a large Q4 jump of 50-55% in EBITDA, driven by the deferred CDMO shipment, normal Q4 seasonality, and additional CDMO sales.
- API margin recovery is tied to CDMO mix: Q4 last year's 27% EBITDA margin was driven by CDMO/CMO at 27% of sales; as CDMO continues growing at 30-40%, such margins could return.
- Balance sheet remains manageable: Net debt to equity is expected at 0.3-0.35x after all capex for Atali and Xanthine by Q4.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Atali stabilization | Startup hiccups resolved | End of Q4 FY26 |
| Xanthine expansion mechanical completion | 9,000 tonnes per annum capacity ready | End of March 2026 |
| Xanthine capacity utilization | Reach 85-90% of 9,000-tonne capacity | By FY28 |
| API quarterly run rate | Reach INR200 crores | A couple more quarters |
| FY26 EBITDA | Largely in line with last year, marginal growth | FY26 full year |
| FY26 CDMO revenue | Meet guidance (exceeding now difficult) | FY26 full year |
| CDMO growth rate | 30-40% range, similar to FY26 | FY27 |
| CDMO customer count | Increase from current 21 | Calendar year 2026 |
| Net debt to equity | 0.3-0.35x post all capex | By Q4 FY26 |
| New CDMO block at Atali | At least one block, not large capex | FY27 |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue | ₹425 cr, vs ₹471 cr a year back |
| EBITDA | ₹103 cr, vs ₹115 cr a year back |
| Profit after tax | ₹44 cr, vs ₹74 cr a year back |
| EBITDA margin | 24.2%, vs 24.4% a year back (per an analyst's math) |
| Gross debt | ₹650 cr (9 months ending) |
| Net debt | ~₹650 cr |
| Net debt to equity | 0.3 to 0.35 (post-capex target) |
| Interim dividend per share | ₹1.5 |
| Xanthine Derivatives revenue share | 49% of turnover |
| Xanthine volume split | 63% beverages, 37% other |
| Xanthine geographical split | 51% export, 49% local sales |
| Xanthine operating run rate | 500 tonnes per month, adding 300 tonnes per month capacity; installed capacity ~9,000 tonnes per annum |
| API and Intermediates revenue share | 39% of turnover |
| API and Intermediates revenue | ~₹167 cr, vs ~₹180 cr a year back like-for-like, decline of 5-6% |
| API subsegment breakup | 52% regulated market, 34% ROW market, 14% non-reg market |
| CDMO/CMO revenue share | 12% of revenue |
| CDMO active projects | 59 total; 40 commercial stage, 19 under development |
| CDMO customers | 21 |
| CDMO shipments (9M FY26) | ₹120-130 cr, plus ₹50 cr |
| Goods in transit (not booked as revenue) | ₹49 cr revenue value, ₹30 cr cost; PBT impact ₹19 cr |
| Atali plant capex | ₹300 cr capitalized of ₹450 cr total outlay |
| Atali monthly opex | ~₹1.5 cr |
| Xanthine total approved capex | ~₹150 cr (both sites) |
| CDMO sales target | ₹1,000 cr |
| Locked-in business percentage | ~50% |